Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Welcome and Introduction to Vi3C

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Feb
12
Today In Oncology
PSMA PET/CT-Guided Radiotherapy After Prostatectomy
Rural Populations Face Greater Barriers as Nonmedical Costs Hinder Cancer Clinical Trial Access
FDA Approves Pembrolizumab With Paclitaxel for Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
A New Risk Model for Esophagectomy Draws on the STS National Database
Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo